Cti Biopharma Corp Stock
Your prediction
Pros and Cons of Cti Biopharma Corp in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cti Biopharma Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cti Biopharma Corp | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | 0.000% | 2.362% | -2.256% | -15.584% | -21.687% | -50.943% | -83.007% |
| Celldex Therapeutics | 0.520% | 1.058% | -13.182% | -12.385% | -13.182% | -51.621% | -6.464% |
| Achieve Life Sciences Inc. | -3.600% | 5.394% | -23.573% | 14.038% | -2.297% | -19.128% | -71.758% |
Comments
CTI BioPharma Corp. (NASDAQ: CTIC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
Show more
Ratings data for CTIC provided by MarketBeat
CTI BioPharma Corp. (NASDAQ: CTIC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
Show more
Ratings data for CTIC provided by MarketBeat
